Vetr Upgrades Valeant
The Vetr crowd downgraded Valeant Pharmaceuticals International, Inc. (NASDAQ: VRX) from 4 stars to 4.5 stars.
The crowd rates Valeant a Buy with a price target of $19.72. Wall Street analysts price the stock's value at $24.58.
See how crowdsourced ratings can help predict the market?
Valeant shares were trading up slightly at $17.75 after Tuesday's close.
For the crowd's full analysis of the stock, click here.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General